中图分类号:
R914
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] World Health Organization. Cancer[EB/OL]. 2018-09-12.https://www.who.int/en/news-room/fact-sheets/detail/cancer.
[2] DICKENS E, AHMED S. Principles of cancer treatment by chemotherapy[J]. Surgery (Oxford), 2018, 36 (3):134-138.
[3] LIU X C, CHENG Y F, LI D A. Anti-Tumor Resistance Mechanisms.Practical Antitumor Drug Treatment[M]. Practical Therapy of Antitumor Drug (实用抗肿瘤药物治疗学). Beijing:People′s Medical Publishing House, 2002:171-181.
[4] HOPKINS A L. Network pharmacology:the next paradigm in drug discovery [J]. Nat Chem Biol, 2008, 4 (11):682-690.
[5] VIEGAS-JUNIOR C, DANUELLO A, BOLZANI V, et al. Molecular hybridization:a useful tool in the design of new drug prototypes [J].Current Med Chem, 2007, 14 (17):1829-1852.
[6] FORTIN S, BERUBE G. Advances in the development of hybrid anticancer drugs [J]. Expert Opin Drug Dis, 2013, 8 (8):1029-1047.
[7] SENKARDES S, KAUSHIK-BASU N, DURMAZ I, et al. Synthesis of novel diflunisalhydrazide-hydrazones as anti-hepatitis C virus agents and hepatocellular carcinoma inhibitors[J]. Eur J Med Chem, 2016, 108:301-308.
[8] MUKHERJEE D D, KUMAR N M, TANTAK M P, et al. Development of novel bis(indolyl)-hydrazide-hydrazone derivatives as potent microtubule-targeting cytotoxic agents against A549 lung cancer cells [J]. Biochemistry, 2016, 55 (21):3020-3025.
[9] PARK E B, KIM K J, JEONG H R, et al. Synthesis, structure determination, and biological evaluation of phenylsulfonyl hydrazide derivatives as potential anti-inflammatory agents [J]. Bioorg Med Chem Lett, 2016, 26 (21):5193-5197.
[10] GUO B, FAN H X, XIN Q S, et al. Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinone sleading to a promising antibacterial agent [J]. J Med Chem, 2013, 56 (6):2642-2650.
[11] GRIGOR′EV A A, SHTYRLIN N V, GABBASOVA R R, et al. Synthesis, antibacterial and antitumor activity of methylpyridinium salts of pyridoxine functionalized 2-amino-6-sulfanylpyridine-3,5-dicarbonitriles[J]. Synthetic Commun, 2018, 48 (17):2288-2304.
[12] YU X L, ZHENG Z C, MEI L Y, et al. Synthesis technology of dexlansoprazole [J].Drugs Clin(现代药物与临床), 2013, 28 (5):661-664.
[13] YANG H L, XU G X, BAO M Y, et al. Design and synthesis of pyridinylisoxazoles and their anticancer activities [J]. Chem J Chin Univ(高等学校化学学报), 2014, 35 (12):2584-2592.
[14] KUMAR R N, REDDY G M, NAGENDAR P, et al. Synthesis of novel pyrido[3′,2′:4,5]furo[3,2-d]pyrimidine derivatives and their cytotoxic activity [J]. J Heterocyclic Chem, 2014, 51 (5):1531-1535.
[15] ZhOU H, DUAN Z G, ZHAO S, et al. Design and synthesis of phenylpyrimidine and their anticancer activity [J]. Chem J Chin Univ(高等学校化学学报), 2015, 36 (9):1694-1701.
[16] KANTEVARI S, CHARY M V, VUPPALAPATI S. A highly efficient regioselective one-pot synthesis of 2,3,6-trisubstituted pyridines and 2,7,7-trisubstituted tetrahydroquinolin-5-ones using K5CoW12O40·3H2O as a heterogeneous recyclable catalyst [J]. Tetrahedron, 2007, 63 (52):13024-13031.
[17] ABDEL-AZIZ H A, ABOUL-FADL T, AL-OBAID A, et al. Design, synthesis and pharmacophoric model building of novel substituted nicotinic acid hydrazones with potential antiproliferative activity [J]. Arch Pharm Res, 2012, 35 (9):1543-1552.
[18] QI B H,YANG Y, HE H, et al. Design, synthesis and antitumor activities of c-Met inhibitors possessing thiazolinone scaffolds [J]. Chin Pharm J (中国药学杂志), 2018,53 (15):1255-1264.
[19] JIA J J, GUO Z Y, LING Y H, et al. Synthesis and anti tumoractivities of quercetin and its derivates [J].Chin Pharm J (中国药学杂志),2016,51(23):2013-2017.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家级大学生创新创业训练计划项目资助(201813276001)
{{custom_fund}}